Table 2.
Associations between baseline clinicopathologic features and BC molecular subtype
| Characteristics | No. of patients (%) n=522 | The Bhargava molecular subtypes | P | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| LUMA 170 (32.5) | LUMB 82 (15.7) | TNB- 17 (3.3) | TNB+ 93 (17.8) | HER2 100 (19.2) | LAHH 17 (3.3) | LBHH 43 (8.2) | |||
| Age group | <0.001a | ||||||||
| <40 | 69 (13.2) | 18 (10.6) | 11 (13.4) | 5 (29.4) | 16 (17.2) | 10 (10.0) | 0 (0.0) | 9 (20.9) | |
| 40-49 | 144 (27.6) | 40 (23.5) | 26 (31.7) | 7 (41.2) | 29 (31.2) | 24 (24.0) | 2 (11.8) | 16 (37.2) | |
| 50-59 | 188 (35.9) | 58 (34.1) | 27 (32.9) | 3 (17.6) | 31 (33.3) | 50 (50.0) | 7 (41.2) | 12 (27.9) | |
| 60-69 | 86 (16.5) | 36 (21.2) | 14 (17.1) | 2 (11.8) | 13 (14.0) | 11 (11.0) | 6 (35.3) | 4 (9.3) | |
| ≥70 | 35 (6.7) | 18 (10.6) | 4 (4.9) | 0 (0.0) | 4 (4.3) | 5 (5.0) | 2 (11.8) | 2 (4.7) | |
| Age | 0.022a | ||||||||
| Young (≤40 Y-O) | 81 (69.8) | 20 (52.6) | 14 (77.8) | 5 (100) | 20 (83.3) | 13 (72.2) | 0 (0.0) | 9 (81.8) | |
| Older (≥70 Y-O) | 35 (30.2) | 18 (47.4) | 4 (22.2) | 0 (0.0) | 4 (16.7) | 5 (27.8) | 2 (100.0) | 2 (18.2) | |
| Lateral | 0.634a | ||||||||
| Right | 234 (44.8) | 75 (44.1) | 35 (42.7) | 8 (47.1) | 38 (40.9) | 45 (45.0) | 11 (64.7) | 22 (51.2) | |
| Left | 285 (54.6) | 93 (54.7) | 47 (57.3) | 9 (52.9) | 55 (59.1) | 55 (55.0) | 6 (35.3) | 20 (46.5) | |
| Bilateral | 3 (0.6) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.3) | |
| Tumor size (cm) | 0.018b | ||||||||
| ≤2 | 261 (50.0) | 99 (58.2) | 40 (48.8) | 8 (47.1) | 45 (48.4) | 35 (35.0) | 11 (64.7) | 23 (53.5) | |
| >2-5 | 242 (46.4) | 66 (38.8) | 40 (48.8) | 7 (41.2) | 45 (48.4) | 58 (58.0) | 6 (35.3) | 20 (46.5) | |
| >5 | 19 (3.6) | 5 (3.0) | 2 (2.4) | 2 (11.8) | 3 (3.2) | 7 (7.0) | 0 (0.0) | 0 (0.0) | |
| Histopathologic type | <0.001b | ||||||||
| NOS | 374 (71.6) | 108 (63.5) | 61 (74.4) | 9 (52.9) | 68 (73.1) | 80 (80.0) | 12 (70.6) | 36 (83.7) | |
| Mucinous | 16 (3.1) | 10 (5.9) | 6 (7.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Lobular | 89 (17.0) | 38 (22.4) | 12 (14.6) | 5 (29.4) | 13 (12.6) | 13 (13.0) | 5 (29.4) | 5 (11.6) | |
| Other | 43 (8.2) | 14 (8.2) | 3 (3.7) | 3 (17.6) | 7 (6.8) | 7 (7.0) | 0 (0.0) | 2 (4.7) | |
| Histologic grade | <0.001 | ||||||||
| I | 56 (10.7) | 33 (19.4) | 10 (12.2) | 1 (5.9) | 4 (4.3) | 3 (3.0) | 1 (5.9) | 4 (9.3) | |
| II | 190 (36.4) | 67 (39.4) | 41 (50.0) | 3 (17.6) | 24 (25.8) | 30 (30.0) | 7 (41.2) | 18 (41.9) | |
| III | 276 (52.9) | 70 (41.2) | 31 (37.8) | 13 (76.5) | 65 (69.9) | 67 (67.0) | 9 (52.9) | 21 (48.8) | |
| Lymph node status | <0.001 | ||||||||
| Negative | 330 (63.2) | 133 (78.2) | 52 (63.4) | 8 (47.1) | 54 (58.1) | 48 (48.0) | 11 (64.7) | 24 (55.8) | |
| 1-3 positive node (s) | 121 (23.2) | 27 (15.9) | 25 (30.5) | 0 (0.0) | 24 (25.8) | 29 (29.0) | 3 (17.6) | 13 (30.2) | |
| >3 positive nodes | 71 (13.6) | 10 (5.9) | 5 (6.1) | 9 (52.9) | 15 (16.1) | 23 (23.0) | 3 (17.6) | 6 (14.0) | |
| Nottingham PI | <0.001 | ||||||||
| Good | 122 (23.4) | 60 (35.3) | 19 (23.2) | 2 (11.8) | 14 (15.1) | 10 (10.0) | 4 (23.5) | 13 (30.2) | |
| Moderate | 281 (53.8) | 90 (52.9) | 52 (63.4) | 6 (35.3) | 53 (57.0) | 53 (53.0) | 9 (52.9) | 18 (41.9) | |
| Poor | 119 (22.8) | 20 (11.8) | 11 (13.4) | 9 (52.9) | 26 (28.0) | 37 (37.0) | 4 (23.5) | 12 (27.9) | |
| Ki67 index | 0.000 | ||||||||
| Low (≤20%) | 271 (51.9) | 121 (71.2) | 54 (65.9) | 6 (35.3) | 32 (34.4) | 35 (35.4) | 6 (35.3) | 17 (39.5) | |
| High (>20%) | 251 (48.1) | 49 (28.8) | 28 (34.1) | 11 (64.7) | 61 (65.6) | 65 (64.6) | 11 (64.7) | 26 (60.5) | |
| LVI | 0.001 | ||||||||
| Negative | 337 (64.6) | 127 (74.9) | 59 (72.0) | 11 (61.1) | 50 (53.8) | 53 (54.3) | 10 (58.8) | 27 (64.3) | |
| Positive | 185 (35.4) | 43 (25.1) | 23 (28.0) | 7 (38.9) | 42 (46.2) | 48 (45.7) | 7 (41.2) | 15 (35.7) | |
| Tumor necrosis | 0.004 | ||||||||
| Negative | 429 (82.2) | 152 (89.4) | 64 (78.0) | 12 (70.6) | 68 (73.1) | 78 (78.0) | 16 (94.1) | 39 (90.7) | |
| Positive | 93 (17.8) | 18 (10.6) | 18 (22.0) | 5 (29.4) | 25 (26.9) | 22 (22.0) | 1 (5.9) | 4 (9.3) | |
| pTNM stage | 0.000 | ||||||||
| I | 134 (25.7) | 66 (38.8) | 17 (20.7) | 1 (5.9) | 20 (21.5) | 12 (12.0) | 6 (35.3) | 12 (27.9) | |
| II | 306 (58.6) | 87 (51.2) | 61 (74.4) | 10 (58.8) | 57 (61.3) | 61 (61.0) | 6 (35.3) | 24 (55.8) | |
| III | 82 (15.7) | 17 (10.0) | 4 (4.9) | 6 (35.3) | 16 (17.2) | 27 (27.0) | 5 (29.4) | 7 (16.3) | |
| Risk | 0.000b | ||||||||
| Low | 24 (4.6) | 19 (11.2) | 4 (4.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.3) | |
| Inter | 359 (68.8) | 140 (82.4) | 73 (89.0) | 8 (47.1) | 54 (58.1) | 49 (49.0) | 11 (64.7) | 24 (55.8) | |
| High | 139 (26.6) | 11 (6.4) | 5 (6.1) | 9 (52.9) | 39 (41.9) | 51 (51.0) | 6 (35.3) | 18 (41.9) | |
| Survival | 0.015a | ||||||||
| Died | 24 (12.3) | 4 (6.3) | 1 (2.8) | 0 (0.0) | 6 (21.4) | 8 (24.2) | 0 (0.0) | 5 (22.7) | |
| Survived | 171 (87.7) | 59 (93.7) | 35 (97.2) | 9 (100) | 22 (78.6) | 25 (75.8) | 4 (100) | 17 (77.3) | |
| Recurrence | 0.881a | ||||||||
| No Relapse | 192 (98.5) | 61 (96.8) | 36 (100) | 9 (100) | 28 (100) | 32 (97.0) | 4 (100) | 22 (100) | |
| Relapse | 3 (1.5) | 2 (3.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (3.0) | 0 (0.0) | 0 (0.0) | |
a
Fisher exact test;
b
Likelihood Ratio.